AbbVie Announces European Commission Approval of RINVOQ (upadacitinib) for the Treatment of…
AbbVie (NYSE: ABBV) today announced the European Commission (EC) approved RINVOQ (upadacitinib, 45 mg and 15 mg and 30 mg ) as the first oral Janus Kinase (JAK) inhibitor for the…
Read More...
Read More...
